Trigger assay for differentiating between rheumatic and non-rheumatic disorders

A rheumatic and rheumatoid technology, applied in the field of trigger measurement for distinguishing rheumatic and non-rheumatic diseases, which can solve problems such as wrong treatment of diseases and patient deterioration

Inactive Publication Date: 2011-07-20
F HOFFMANN LA ROCHE & CO AG
View PDF15 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Otherwise the patient may suffer from the wrong treatment which may even worsen the condition

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Trigger assay for differentiating between rheumatic and non-rheumatic disorders
  • Trigger assay for differentiating between rheumatic and non-rheumatic disorders
  • Trigger assay for differentiating between rheumatic and non-rheumatic disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0278] Example 1: Immune multi-parameter chip technology IMPACT-general operation

[0279] A black polystyrene chip with a surface area of ​​approximately 2.5 x 6 mm was completely coated with a layer of streptavidin. On this streptavidin surface we applied the same reagent dots in rows (approximately 20 dots per reagent per row) using the ink-jet technique. Each spot is approximately 150 μm in diameter and contains a biotinylated binding reagent capable of specifically binding to an analyte (eg, antigen or antibody) in the sample.

[0280] Each sample was diluted with sample dilution buffer and 40 μl of the diluted sample was applied and incubated per chip. Assays were performed on automated pre-prototype instruments.

[0281] Detection Specific Reagents

[0282] Sample Dilution Buffer: 50mM Tris, 30mM MES, 50mM NaCl, 5mM EDTA, 0.5% Casein, 0.1% Detergent (Polydocanol), 0.2% Preservative (Oxypyrion and Methylisothiazole Hydrochloride (MIT))

[0283] Wash buffer: 10mM Tris...

Embodiment 2

[0286] Embodiment 2: Composition of multi-parameter array

[0287] After the multiplex array kit was produced, the sample set was assayed for the following analytes:

[0288] Multi-1: RF-IgM, CRP, SAA

[0289] Multiplex-2: 5 different anti-CCP-autoantibodies: 5 different peptides (cyclic citrullinated peptides) are coated onto the surface

[0290] Multiplex-3: Anti-centromere B peptide, anti-SSA52, anti-Jo-1, anti-SSA60, anti-SSB, anti-Scl70, anti-RNP / Sm, anti-dsDNA

[0291] Multiplex 4: IL-6, prohyaluronan (HA)-MMP-3, E-selectin

Embodiment 3

[0292] Example 3: Study Population

[0293] patient

[0294] Patients were enrolled in a prospective longitudinal study in six European trial centers according to a harmonized standard operating procedure (SOP). Samples from patients with osteoarthritis (OA) were collected at Bristol (UK), samples from patients with autoimmune disease and controls were collected at Chur (CH), and samples from patients with RA were collected at five centres. In this experiment, only the samples at the time of enrollment were used. Inclusion criteria for the RA cohort were the presence of a minimum of four ACR criteria plus a retrospective diagnosis after 2 years of follow-up (Hochberg, M.C. et al., Arthritis Rheum. 35 (1992) 498-502). All RA, autoimmune, and control patients had established disease with a positive diagnosis verified by each center. The trial was approved by the ethics committee of each participating center.

[0295] case report form

[0296] A standard case repor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides for a method for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject including determining as to whether at least one autoantibody or antigen which is indicative for at least one rheumatic disorder is present in a sample obtained from the subject, wherein the presence of the autoantibody or antigen allows to exclude a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject. Accordingly, it provides for a method that triggers the next steps in diagnosing the cause of a musculoskeletal complaint of a subject-either further diagnosis of a rheumatic disorder or of a non-rheumatic disorder to confirm the initial diagnosis. Also provided is a kit for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject as well as uses of the kit.

Description

technical field [0001] The invention provides a method for excluding a non-rheumatic condition as a cause of a musculoskeletal disorder in a subject, the method comprising detecting the presence or absence of at least one autoantibody or antigen indicative of at least one rheumatic condition in a sample obtained from a patient, The presence of said autoantibodies or antigens therein makes it possible to rule out a non-rheumatic condition as the cause of the patient's musculoskeletal disease. Accordingly, the present invention provides methods of diagnosing a predisposition to a musculoskeletal disorder in a subject triggering the next step of further diagnosing a rheumatic or non-rheumatic disorder to confirm the initial diagnosis. The present invention also provides a kit for excluding non-rheumatic disorders as the cause of a musculoskeletal disease in a patient and the use of the kit. Background technique [0002] With so many patients seeking medical care for musculoske...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/53G01N33/68
CPCG01N33/564
Inventor J·卡尔U·克劳泽V-P·格鲁纳特
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap